Development of cell-cycle inhibitors for cancer therapy

Current Oncology

Volumn 16, Issue 2, 2009, Pages 36-43

  Dickson, M A ^a   Schwartz, G K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cell cycle; Cyclin dependent kinases; Cyclins; Phase I clinical trials; Phase II clinical trials

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; AZD 5438; BRYOSTATIN 1; CAPECITABINE; CARBOPLATIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; INDISULAM; IRINOTECAN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PACLITAXEL; ROSCOVITINE; SCH 727965; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; ANOREXIA; APOPTOSIS; ASTHENIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FATIGUE; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; INFECTION; LETHARGY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UTERUS CANCER;

EID: 67650777303     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
2. Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKS), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIS). Oncogene 1995;11:211-19.
3. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999;39:295-312.
4. Kaldis P, Russo AA, Chou HS, Pavletich NP, Solomon MJ. Human and yeast CDK-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 1998;9:2545-60.
5. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 1974;71:1286-90.
6. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
7. Sherr CJ. The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
8. Elledge SJ, Harper JW. The role of protein stability in the cell cycle and cancer. Biochim Biophys Acta 1998;1377:M61-70.
9. Ford HL, Pardee AB. The S phase: beginning, middle, and end: a perspective. J Cell Biochem Suppl 1998;30-31:1-7.
10. Ford HL, Pardee AB. Cancer and the cell cycle. J Cell Biochem Suppl 1999;32-33:166-72.
11. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG Jr, Livingston DM. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A - dependent protein kinase. Cell 1994;78:161-72.
12. Dynlacht BD, Flores O, Lees JA, Harlow E. Differential regulation of E2F transactivation by cyclin/CDK2 complexes. Genes Dev 1994;8:1772-86.
13. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica - Worms H. Cyclin A/ CDK2 binds directly to E2F-1 and inhibits the DNA- binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol 1994;14: 8420-31.
14. Kitagawa M, Higashi H, Suzuki - Takahashi I, et al. Phosphorylation of E2F-1 by cyclin A - CDK2. Oncogene 1995;10:229-36.
15. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
16. 2-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001;21:3445-50.
17. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM- Chk2-CDC25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-7.
18. Zhou XY, Wang X, Hu B, Guan J, Iliakis G, Wang Y. An ATM- independent S-phase checkpoint response involves CHK1 pathway. Cancer Res 2002;62:1598-603.
19. Andersen SS. Spindle assembly and the art of regulating microtubule dynamics by MAPS and Stathmin/Op18. Trends Cell Biol 2000;10:261-7.
20. Rudner AD, Murray AW. The spindle assembly checkpoint. Curr Opin Cell Biol 1996;8:773-80.
21. Nicklas RB. How cells get the right chromosomes. Science 1997;275:632-7.
22. Blagden SP, Glover DM. Polar expeditions - provisioning the centrosome for mitosis. Nat Cell Biol 2003;5:505-11.
23. Giet R, McLean D, Descamps S, et al. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J Cell Biol 2002;156:437-51.
24. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in Aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995;81:95-105.
25. Reed JC, Bischoff JR. BIRinging chromosomes through cell division - and survivin' the experience. Cell 2000;102:545-8.
26. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-7.
27. CDC2 survival checkpoint in cancer. Cancer Cell 2002; 2:43-54.
28. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
29. Harper JW, Elledge SJ. CDK inhibitors in development and cancer. Curr Opin Genet Dev 1996;6:56-64.
30. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg 2001;234:10-20.
31. Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 2002;4:14-17.
32. Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
33. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999;96:4325-9.
34. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002;190:160-9.
35. Kobor MS, Greenblatt J. Regulation of transcription elongation by phosphorylation. Biochim Biophys Acta 2002;1577:261-75.
36. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005;106:2513-19.
37. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
38. Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2008;[in press].
39. Burdette - Radoux S, Tozer RG, Lohmann RC, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004;22:315-22.
40. Grendys EC Jr, Blessing JA, Burger R, Hoffman J. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98:249-53.
41. Dispenzieri A, Gertz MA, Lacy MQ, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006;91:390-3.
42. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-45.
43. Ambrosini G, Seelman SL, Qin LX, Schwartz GK. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res 2008;68:2312-20.
44. George S, Kasimis BS, Cogswell J, et al. Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008; 9:160-5.
45. El-Rayes BF, Gadgeel S, Parchment R, Lorusso P, Philip PA. A phase I study of flavopiridol and docetaxel. Invest New Drugs 2006;24:305-10.
46. Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13: 5841-6.
47. Bible KC, Lensing JL, Nelson SA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005;11:5935-41.
48. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007;13:4467-73.
49. Jackman KM, Frye CB, Hunger SP. Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50:772-8.
50. Yang X, Zhao X, Phelps MA, et al. A novel liposomal formulation of flavopiridol. Int J Pharm 2009;365:170-4.
51. Terret C, Zanetta S, Roche H, et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 2003;39:1097-104.
52. Haddad RI, Weinstein LJ, Wieczorek TJ, et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 2004;10:4680-7.
53. Smyth JF, Aamdal S, Awada A, et al. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol 2005; 16: 158-61.
54. Talbot DC, von Pawel J, Cattell E, et al. A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2007;13:1816-22.
55. Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J. A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer 2007;96:559-66.
56. Siegel - Lakhai WS, Zandvliet AS, Huitema AD, et al. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. Br J Cancer 2008;98:1320-6.
57. Camidge DR, Pemberton M, Growcott J, et al. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mono-nucleocytes of healthy male volunteers. Cancer Chemother Pharmacol 2007;60:479-88.
58. Camidge DR, Smethurst D, Growcott J, et al. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemother Pharmacol 2007;60:391-8.
59. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008;26:59-65.
60. Asiedu C, Biggs J, Lilly M, Kraft AS. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res 1995;55:3716-20.
61. Jayson GC, Crowther D, Prendiville J, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995;72:461-8.
62. El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA. Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res 2006;12:7059-62.
63. Roberts JD, Smith MR, Feldman EJ, et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res 2006;12:5809-16.
64. Ajani JA, Jiang Y, Faust J, et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 2006;24:353-7.
65. Ku GY, Ilson DH, Schwartz LH, et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2008;62:875-80.
66. McClue S, Fischer P, Blake D, et al. Studies on the mechanism of action of CYC202 (R-roscovitine) [abstract 666]. Amer Assoc Cancer Res 2002;43:3303.
67. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumour properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
68. Alvi A, Austen B, Weston VJ, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005; 105:4484-91.
69. Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747-55.
70. Kim EH, Kim SU, Shin DY, Choi KS. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004;23:446-56.
71. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II - dependent transcription and down-regulation of Mcl-1. Cancer Res 2005;65:5399-407.
72. Maier A, Kelter G, Gianella - Borradori A. Antitumour activity of CYC202, a cyclin-dependent kinase inhibitor, in human tumor xenografts in vitro [abstract 713]. Amer Assoc Cancer Res 2003;44:.
73. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007;96:29-37.
74. Siegel - Lakhai W, Rodenstein D, Beijnen J, Gianella - Borradori A, Schellens J, Talbot D. Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC) [abstract 2060]. Proc Am Soc Clin Oncol 2005;23:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+ Meeting/Abstracts?&vmview=abst_detail_view&confID= 34&abstractID=30982; cited February 20, 2009]
75. Toogood PL, Harvey PJ, Repine JT, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005;48:2388-406.
76. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumour activity in human tumor xenografts. Mol Cancer Ther 2004;3: 1427-38.
77. VanderWel SN, Harvey PJ, McNamara DF, et al. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J Med Chem 2005;48:2371-87.
78. Marzec M, Kasprzycka M, Lai R, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006;108:1744-50.
79. O'Dwyer P, LoRusso P, DeMichele A, et al. A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991 [abstract 3550]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/ Abstracts?&vmview=abst_detail_view&confID=47&abstractID= 35816; cited February 20, 2009]
80. Shapiro G, Bannerji R, Small K, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies [abstract 3532]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview= abst_detail_view&confID=55&abstractID=32136; cited February 20, 2009]